Advertisement

An anthology from Naunyn-Schmiedeberg’s archives of pharmacology

O. Schaumann (1940) Über eine neue Klasse von Verbindungen mit spasmolytischer und zentral analgetischer Wirkung unter besonderer Berücksichtigung des 1-methyl-4-phenyl-piperidin-4-carbonsäure-äthylesters (Dolantin). Archiv f. experiment. Path. u. Pharmakol. 196: 109–136
  • Martin Michaelis
  • Bernward Schölkens
  • Karl Rudolphi
Special Article

Otto Schaumann: short biography

Otto Schaumann (1891–1977) studied chemistry at the University of Vienna. He got his Ph.D. in 1914 and spent a post-doctorate at the Institute of Pharmacology under Hans Horst Meyer. From 1925–1946, he worked as head of a pharmacological laboratory at Farbwerke Hoechst, Frankfurt/Main-Höchst (Fig.  1). In 1941, he wrote a habilitation thesis in medicine. Schaumann discovered the analgesic effects of Dolantin® (pethidine, meperidine) that was synthesized in 1932 as a potentially spasmolytic agent by the medicinal chemist Otto Eisleb (1887–1948) at Farbwerke Hoechst. He profiled the compound preclinically but, interestingly enough, also accompanied the clinical development of pethidine closely until and beyond its first launch as a parenteral injectable formulation in 1939 and the following launches as suppositories and drops in 1942, thus, already practicing translational science. Together with the pharmacologist Ernst Lindner, he was also involved in the...

Keywords

Antispasmodic activity Pethidine Morphine-like analgesic effects Otto Schaumann 

Notes

Acknowledgment

The authors thank Prof. Dr. Ernst Lindner for providing valuable information as a contemporary witness of Otto Schaumann’s work.

References

  1. Gulland JM, Robinson R (1925) The constitution of codeine and thebaine. Mem Proc Manch Lit Philos Soc 69:79–86Google Scholar
  2. Gutstein HB, Akil H (2001) Opioid analgesics. In: Hardman JG, Limbard LE (eds) Goodman and Gillman’s the pharmacologic basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 569–620Google Scholar
  3. Keil W, Kluge A (1934) Über die anwendung des mäuseschwanzphänomens zur auswertung von morphin- und skopolaminpräparaten. Naunyn Schmiedebers Arch Pharmakol 174:493–501Google Scholar
  4. McQuay H (1999) Opioids in pain management. Lancet 353:2229–2232PubMedCrossRefGoogle Scholar
  5. Schaumann O (1957) Morphin und morphinähnlich wirkende Verbindungen. Springer, Berlin Heidelberg New YorkGoogle Scholar
  6. Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, Reidenberg MM (1977) Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 86:738–741PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Martin Michaelis
    • 1
  • Bernward Schölkens
    • 1
  • Karl Rudolphi
    • 1
  1. 1.Science and Medical AffairsSanofi–Aventis Deutschland GmbHFrankurt am MainGermany

Personalised recommendations